Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Ensysce Biosciences, Inc. (ENSC : NSDQ)

• Company Description    Ensysce Biosciences is a clinical-stage biotech company using its proprietary technology platforms to develop safer prescription drugs. The company is involved in developing tamper-proof opioids which prevent both drug abuse and overdoses. Ensysce Biosciences, formerly known as Leisure Acquisition Corp., is based in SAN DIEGO. Number of Employees: 10

• Price / Volume Information    Yesterday's Closing Price: $0.26 Daily Weekly Monthly 20 Day Moving Average: 1,403,932 shares Shares Outstanding: 15.37 (millions) Market Capitalization: $4.02 (millions) Beta: 0.78 52 Week High: $2.75 52 Week Low: $0.23 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -7.63% -8.31% 12 Week -29.66% -31.58% Year To Date -71.59% -72.62%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 7946 IVANHOE AVENUE SUITE 201 - LA JOLLA,CA 92037 USA ph: 858-263-4196 fax: - shannon@mzgroup.us http://www.ensysce.com

• General Corporate Information    Officers Lynn Kirkpatrick - Chief Executive Officer; President and Director Bob Gower - Chairman and Director David Humphrey - Chief Financial Officer; Secretary and Treasurer William Chang - Director Adam Levin - Director Peer Information Ensysce Biosciences, Inc. (CORR.) Ensysce Biosciences, Inc. (RSPI) Ensysce Biosciences, Inc. (CGXP) Ensysce Biosciences, Inc. (BGEN) Ensysce Biosciences, Inc. (GTBP) Ensysce Biosciences, Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 293602504 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/26 Next Expected EPS Date: 08/12/26 Share - Related Items Shares Outstanding: 15.37 Most Recent Split Date: 12.00 (0.07:1) Beta: 0.78 Market Capitalization: $4.02 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $0.09 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-1.53 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 1.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/12/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: - Price/Cash Flow: - Price / Sales: 0.85 EPS Growth vs. Year Ago Period: 62.59% vs. Previous Quarter: 30.67% Sales Growth vs. Year Ago Period: -27.20% vs. Previous Quarter: -48.94% ROE 06/30/26 - - 03/31/26 - -766.45 12/31/25 - -426.62 ROA 06/30/26 - - 03/31/26 - -256.59 12/31/25 - -195.53 Current Ratio 06/30/26 - - 03/31/26 - 0.71 12/31/25 - 1.59 Quick Ratio 06/30/26 - - 03/31/26 - 0.71 12/31/25 - 1.59 Operating Margin 06/30/26 - - 03/31/26 - -250.39 12/31/25 - -200.87 Net Margin 06/30/26 - - 03/31/26 - -250.39 12/31/25 - -200.87 Pre-Tax Margin 06/30/26 - - 03/31/26 - -250.39 12/31/25 - -200.83 Book Value 06/30/26 - - 03/31/26 - -0.07 12/31/25 - 0.63 Inventory Turnover 06/30/26 - - 03/31/26 - - 12/31/25 - - Debt-to-Equity 06/30/26 - - 03/31/26 - - 12/31/25 - 0.00 Debt-to-Capital 06/30/26 - - 03/31/26 - - 12/31/25 - 0.00

Powered by Zacks Investment Research ©